Literature DB >> 22884617

Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain.

Emily M Johansson1, Elisabeth Reyes-Irisarri, Guadalupe Mengod.   

Abstract

There are eleven families of phosphodiesterases that regulate cellular levels of cyclic nucleotides by degradation of cAMP or cGMP. Knowledge of the expression sites of different PDE genes in brain is of special importance for studies on development of specific inhibitors considering that, for example, PDE4 inhibitor treatments exhibit profound anti-inflammatory effects. To address possible species differences we examined the expression of mRNAs coding for the cAMP specific PDE4 and PDE7 families since inhibitors have been used in clinic for schizophrenia, mood disorders, cognition and inflammatory diseases treatment. We have compared the expression of these PDEs in mouse brain by in situ hybridization histochemistry in comparison with rat brain and found that their neuroanatomical distribution differs in a few areas.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884617     DOI: 10.1016/j.neulet.2012.07.050

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  22 in total

Review 1.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

2.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

3.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

Review 4.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

5.  Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities.

Authors:  Christopher M Olsen; Qing-Song Liu
Journal:  Front Biol (Beijing)       Date:  2016-10-17

Review 6.  Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review.

Authors:  Nazanin Momeni Roudsari; Naser-Aldin Lashgari; Saeideh Momtaz; Mohammad Hosein Farzaei; André M Marques; Amir Hossein Abdolghaffari
Journal:  Daru       Date:  2019-07-04       Impact factor: 3.117

7.  Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.

Authors:  Hao Huang; Qian Hong; Hong-Ling Tan; Cheng-Rong Xiao; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

8.  Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival.

Authors:  E M Medina-Rodríguez; F J Arenzana; J Pastor; M Redondo; V Palomo; R García de Sola; C Gil; A Martínez; A Bribián; F de Castro
Journal:  Cell Mol Life Sci       Date:  2013-05-10       Impact factor: 9.261

Review 9.  Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics.

Authors:  Massimo Ubaldi; Nazzareno Cannella; Roberto Ciccocioppo
Journal:  Prog Brain Res       Date:  2015-11-26       Impact factor: 2.453

10.  Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor.

Authors:  David J Titus; Nicole M Wilson; Julie E Freund; Melissa M Carballosa; Kevin E Sikah; Concepcion Furones; W Dalton Dietrich; Mark E Gurney; Coleen M Atkins
Journal:  J Neurosci       Date:  2016-07-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.